549 related articles for article (PubMed ID: 19584324)
21. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
24. [JAK2 inhibitors in the treatment of myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2012 Oct; 53(10):1600-7. PubMed ID: 23037732
[No Abstract] [Full Text] [Related]
25. Diabetes research. Researchers puzzle over possible effect of Gleevec.
Couzin J
Science; 2005 Mar; 307(5716):1711. PubMed ID: 15774738
[No Abstract] [Full Text] [Related]
26. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
27. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
Tefferi A
Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
[TBL] [Abstract][Full Text] [Related]
28. CML: imatinib mesylate (Glivec) or something else?
Ghosh A
Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
[No Abstract] [Full Text] [Related]
29. A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.
Gangat N; Phelps A; Lasho TL; Finke CM; Vallapureddy R; Hanson CA; Ketterling RP; Patnaik MM; Pardanani A; Tefferi A
Blood Cancer J; 2019 Jan; 9(2):11. PubMed ID: 30679417
[No Abstract] [Full Text] [Related]
30. Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.
Inami M; Inokuchi K; Okabe M; Kosaka F; Mitamura Y; Yamaguchi H; Dan K
Leukemia; 2007 May; 21(5):1103-4. PubMed ID: 17301812
[No Abstract] [Full Text] [Related]
31. [Targeting Ras related proteins for leukemia therapy].
Kimura S; Maekawa T
Rinsho Ketsueki; 2005 Mar; 46(3):179-86. PubMed ID: 16447712
[No Abstract] [Full Text] [Related]
32. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients.
Ebid GT; Ghareeb M; Salaheldin O; Kamel MM
Int J Clin Exp Pathol; 2015; 8(9):11555-9. PubMed ID: 26617890
[TBL] [Abstract][Full Text] [Related]
33. JAK-2V617F mutation in RARS-t: a target for Imatinib therapy?
Cannizzo E; Carulli G; AzzarĂ A; Galimberti S; Zucca A; Petrini M
Leuk Res; 2008 Oct; 32(10):1636-7. PubMed ID: 18433865
[No Abstract] [Full Text] [Related]
34. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Walz C; Cross NC; Van Etten RA; Reiter A
Leukemia; 2008 Jul; 22(7):1320-34. PubMed ID: 18528425
[TBL] [Abstract][Full Text] [Related]
35. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
36. Bench to bedside: BRCA: from therapeutic target to therapeutic shield.
Shah NP
Nat Med; 2008 May; 14(5):495-6. PubMed ID: 18463659
[No Abstract] [Full Text] [Related]
37. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
38. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
James C
Hematology Am Soc Hematol Educ Program; 2008; ():69-75. PubMed ID: 19074061
[TBL] [Abstract][Full Text] [Related]
39. Current treatment of myeloproliferative neoplasias: three scenarios.
Xicoy B; Zamora L
Med Clin (Barc); 2020 Feb; 154(4):131-133. PubMed ID: 31351663
[No Abstract] [Full Text] [Related]
40. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]